Profile
Erin Fleming is the founder of ProJenX, Inc. and holds the title of Senior Director-Operations, VP-Rsch & Dev at the company.
Erin Fleming active positions
| Companies | Position | Start |
|---|---|---|
ProJenX, Inc.
 ProJenX, Inc. Miscellaneous Commercial ServicesCommercial Services ProJenX, Inc. is a clinical-stage biotechnology company that focuses on developing targeted therapies for untreatable brain diseases, with a particular emphasis on ALS. The company is based in Nissequogue, NY. ProJenX's lead therapy candidate, Prosetin, is a first-in-class kinase inhibitor that is being developed for people living with ALS. The company's innovative, patient-specific, cell-based drug discovery platform is at the heart of its approach to research and drug development for ALS and other debilitating brain diseases. The company was founded in 2021 by Erin Fleming and Valerie Estess, and the CEO is Stan E. Abel. | Founder | 2020-12-31 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
ProJenX, Inc.
ProJenX, Inc. Miscellaneous Commercial ServicesCommercial Services ProJenX, Inc. is a clinical-stage biotechnology company that focuses on developing targeted therapies for untreatable brain diseases, with a particular emphasis on ALS. The company is based in Nissequogue, NY. ProJenX's lead therapy candidate, Prosetin, is a first-in-class kinase inhibitor that is being developed for people living with ALS. The company's innovative, patient-specific, cell-based drug discovery platform is at the heart of its approach to research and drug development for ALS and other debilitating brain diseases. The company was founded in 2021 by Erin Fleming and Valerie Estess, and the CEO is Stan E. Abel. | Commercial Services |
- Stock Market
- Insiders
- Erin Fleming
